Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Trading DecisionHold
Generated at:2026-04-17 17:47:17
Analysis based on integrated data from technical, fundamental, news sentiment, and debate reports. Data time range includes recent price action, upcoming Q1 2026 earnings expectations, and consensus analyst targets. Data completeness is high, incorporating multiple perspectives for a balanced view.
Summary

Pfizer, Inc. is fairly valued in a technical consolidation phase ahead of a high-impact earnings event. The prudent strategy is to Hold within a $27.00 - $28.50 range, with a base case 3-month target price of $27.50 (US Dollar). A stop-loss price is suggested at $27.00 (US Dollar). The confidence level is 0.65 (moderate confidence). The risk score is 0.60 (moderately high risk).

Operation strategy
  • For Existing Shareholders: Maintain position.
  • For New Investors: Wait for a clearer catalyst; do not initiate new long positions at this level.
  • Monitor for Breakout/Breakdown: A sustained close above $28.50 on strong volume could signal a move toward $29.50-$30.00 and would warrant a re-evaluation toward a Buy.
  • Monitor for Breakout/Breakdown: A sustained close below $27.00 would target the $26.00-$26.50 support zone and increase downside risk.
  • Re-assess Post-Earnings: The investment thesis should be revisited after the Q1 2026 earnings release and management guidance, which will provide the next fundamental data point to drive price direction.

Core Support

Reasoning summary
  • Valuation Defines the Range: The fundamental report calculates a reasonable P/E-based valuation range of $21.76 to $29.92 with a target of $28.50. The current price ($27.56) sits in the upper half of this range, indicating fair value but no significant margin of safety.
  • Valuation Defines the Range: The news analysis notes a consensus analyst target range of $26-$27. Combining these, a $27.00 - $28.50 trading band is justified by the numbers.
  • Technical Setup Suggests Consolidation, Not Breakout: The technical picture is neutral-to-cautious. The ADX of 8.87 conclusively shows a lack of strong trend. The negative MACD histogram signals fading short-term momentum.
  • Technical Setup Suggests Consolidation, Not Breakout: The stock is consolidating between clear support ($27.00-$27.10) and resistance ($28.38-$28.64).
  • Imminent Catalyst with Asymmetric Risk: The dominant near-term factor is the Q1 2026 earnings report (expected early May). News sentiment is neutral to slightly negative, anticipating a double-digit profit decline.
  • Imminent Catalyst with Asymmetric Risk: The market has likely priced in a messy quarter, but the reaction will be binary. The risk is skewed to the downside if results or guidance disappoint the already-low expectations.
  • Dividend Provides a Floor, Not a Catalyst: The high dividend yield (implied ~6% at current price) is a key supportive element. It should provide a valuation floor near $26.00, corresponding with the BofA target and the lower Bollinger Band.
  • Dividend Provides a Floor, Not a Catalyst: The dividend is a defensive characteristic, not a growth catalyst, and does not justify aggressive buying at current levels.
  • Resolving the Bull-Bear Debate: The synthesis is a Hold—acknowledging the risks the Bear cites (fading momentum and earnings risk) but recognizing the value support the Bull emphasizes (dividend support and strategic pipeline potential).